Cancer Center News

Two new CHOP Cancer Center case reports show that picking the right genetic test matters – using the wrong assay can miss actionable alterations and change treatment options.

Children’s Hospital of Philadelphia is pleased to announce that four of its Cancer Center clinicians and researchers were awarded $1.8 million in research grants from Braden’s Hope for Childhood Cancer, a Kansas City-based nonprofit that funds cutting-edge pediatric cancer research and raises community awareness.

Researchers at Children’s Hospital of Philadelphia (CHOP) identified promising methods to enhance the effectiveness of chimeric antigen receptor (CAR) T cell therapy in neuroblastoma, a deadly pediatric cancer.

Parents Brad and Debbie, whose daughter Sarah underwent surgery to remove a brain tumor, share their story.

Children with Acute Myeloid Leukemia (AML) are treated with anthracyclines, which can harm the heart. CHOP researchers found dexrazoxane lowers heart risks in these patients.

Earlier this month, more than 1000 local philanthropists, corporate leaders and patient families came together for an evening of inspirational storytelling and impact at Children’s Hospital of Philadelphia’s (CHOP) signature fundraiser, the Carousel Ball. The event raised more than $7 million directly benefiting pediatric care, research and education at CHOP.

Last Sunday, more than 290 teams comprised of over 8,000 supporters participated in Children’s Hospital of Philadelphia (CHOP) Cancer Center’s largest fundraiser, the Parkway Run & Walk, presented by Citadel Credit Union. More than $1.8 million was raised to fund and directly support pediatric research and care for those battling cancer.

Researchers at Children’s Hospital of Philadelphia (CHOP) found that combining a specialized diet with an approved medication interrupts the growth of high-risk neuroblastoma, a deadly pediatric cancer, by reprogramming tumor behavior.

CHOP researchers developed CDX0239-PBD, a novel antibody-drug conjugate that demonstrates exceptional effectiveness against cancers expressing the ALK protein, achieving durable tumor responses in preclinical models. This breakthrough could pave the way for new precision medicine treatments, enhancing patient outcomes and reducing the side effects associated with existing therapies.

A new program within the Cancer Center at Children’s Hospital of Philadelphia (CHOP) will support caregivers to safely and comfortably manage their child’s leukemia. It’s called Backpacks With Barbara, a first-of-its-kind initiative that will provide 300 custom-designed, kid-friendly and medically safe backpacks to patients at CHOP undergoing blinatumomab therapy, a cutting-edge immunotherapy used to treat B-cell acute lymphoblastic leukemia.